Favorable effects in COVID-19 may be also expected for the PDE4 inhibitors which modulate processes in various immune cells including neutrophils and inhibit an activation of NF-κB pathway mediating the production of pro-inflammatory cytokines and ROS [217]. This evidence concerns the gene PDE4A and COVID-19.